Cyclosporin for Crohn's disease.
Eight patients with active uncomplicated Crohn's disease, who were resistant to or intolerant of conventional treatment, were treated for 6 weeks with oral cyclosporin (mean dose 8.2 mg kg-1 day-1). Seven of the eight patients responded to treatment with cyclosporin by symptomatic improvement, weight gain and a return of serum C-reactive protein concentration towards normal. All patients relapsed on stopping cyclosporin. No serious side-effects were encountered. This favourable early experience justifies further trials using cyclosporin for active Crohn's disease.
Allison
M C
MC
Academic Department of Medicine, Royal Free Hospital, London, UK.
Pounder
R E
RE
D000293:Adolescent; D000328:Adult; D003424:Crohn Disease / Q000188:drug therapy*; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male
D016572:Cyclosporine